Stocks
Allogene Therapeutics (ALLO) Debt/EBITDA US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| Debt/EBITDA | 2.99 | 3.90 | 4.36 | 1.43 | 1.18 | 0.77 | |||
| Changes by years, y/y, % | -9% | +31% | +12% | -67% | -18% | -18.6% | |||
Allogene Therapeutics. Debt/EBITDA
Allogene Therapeutics. Debt/EBITDA, changes, %
Allogene Therapeutics (ALLO) Debt/EBITDA US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| Debt/EBITDA | 1.13 | 1.16 | 1.07 | 1.37 | 0.77 | 0.77 | ||
| Changes by years, y/y, % | -26% | -22% | -11% | +20% | -32% | |||
| Changes by quarters, q/q, % | -1% | +3% | -8% | +28% | -44% | |||
